AR061973A1 - Compuesto de 2-arilindol sustituido en la posicion 5, composicion farmaceutica que lo comprende, compuestos intermedios y procedimiento para la preparacion de los mismos - Google Patents
Compuesto de 2-arilindol sustituido en la posicion 5, composicion farmaceutica que lo comprende, compuestos intermedios y procedimiento para la preparacion de los mismosInfo
- Publication number
- AR061973A1 AR061973A1 ARP070103095A ARP070103095A AR061973A1 AR 061973 A1 AR061973 A1 AR 061973A1 AR P070103095 A ARP070103095 A AR P070103095A AR P070103095 A ARP070103095 A AR P070103095A AR 061973 A1 AR061973 A1 AR 061973A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- cooh
- same
- phenyl
- hydroxyl
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 3
- 239000002131 composite material Substances 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- -1 nitro, amino Chemical group 0.000 abstract 7
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 5
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 4
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 abstract 3
- 125000000217 alkyl group Chemical group 0.000 abstract 3
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 3
- 125000006274 (C1-C3)alkoxy group Chemical group 0.000 abstract 2
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 2
- 125000005843 halogen group Chemical group 0.000 abstract 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 2
- 125000000896 monocarboxylic acid group Chemical group 0.000 abstract 2
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 abstract 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 abstract 1
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical group C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 abstract 1
- 125000003545 alkoxy group Chemical group 0.000 abstract 1
- 125000004429 atom Chemical group 0.000 abstract 1
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 abstract 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 abstract 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 1
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 150000002367 halogens Chemical group 0.000 abstract 1
- 150000004677 hydrates Chemical class 0.000 abstract 1
- 230000004054 inflammatory process Effects 0.000 abstract 1
- 125000001624 naphthyl group Chemical group 0.000 abstract 1
- 229940094443 oxytocics prostaglandins Drugs 0.000 abstract 1
- 230000036407 pain Effects 0.000 abstract 1
- 150000003180 prostaglandins Chemical class 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
- 125000001424 substituent group Chemical group 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
- 230000024883 vasodilation Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/12—Radicals substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Rheumatology (AREA)
- Cardiology (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Heart & Thoracic Surgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Indole Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Estos compuestos pueden utilizarse como reguladores de las prostaglandinas, para mejorar procesos inflamatorios, de vasodilatación y en terapia del dolor. Reivindicación 1: Compuesto de 2-arilindol sustituido en la posición 5, de fórmula (1), en la que X es un átomo de halógeno o un grupo alquilo C₁₋₃, trifluorometilo, nitro, amino, ciano, dialquil C₁₋₃amino, hidroxilo, alcoxilo C₁₋₃, fenilo o alquil C₁₋₃fenilo; Y y Z, que pueden ser iguales o diferentes, son un átomo de H o halógeno, o un grupo alquilo C₁₋₃, trifluorometilo, nitro, amino, dialquil C₁₋₃amino, hidroxilo, alcoxilo C₁₋₃, fenilo, COOH, alquil C₁₋₃-COOH, alquenil C₂₋₃-COOH, COOR, CONH₂, SO₂CH₃, SO₂NHCH₃ o NHSO₂CH₃; W es un átomo de O ó un grupo CH₂ o NH; R es un átomo de hidrógeno o un grupo alquilo C₁₋₆ o cicloalquilo C₃₋₇ sustituido opcionalmente con de 1 a 3 grupos hidroxilo; A es un grupo fenilo, naftilo o piridino sustituido opcionalmente con de 1 a 3 sustituyentes, que pueden ser iguales o diferentes, seleccionados de entre halógeno, alquilo C₁₋₆ sustituido opcionalmente con de 1 a 3 grupos hidroxilo, trifluorometilo, nitro, amino, dialquil C₁₋₃amino, hidroxilo, alcoxilo C₁₋₃, benciloxilo, COOH, COOR, SO₂CH₃, SO₂NHCH₃, NHSO₂CH₃, POR¹R², OPOR¹R², alquil C₁₋₆-COOH, alquenil C₂₋₆-COOH, fenilo y alquil C₁₋₃fenilo, en el que a su vez, R¹ y R² que pueden ser iguales o diferentes, son alquilo C₁₋₃; y sus sales de adición, estereoisómeros, enantiómeros, hidratos, solvatos y formas polimórficas fisiológicamente aceptables.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT001368A ITMI20061368A1 (it) | 2006-07-14 | 2006-07-14 | Composto 2-arilindolico sostituito in posizione 5, composizione farmaceutica che lo comprende nonche' composti intermedi e procedimento per prepararlo |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR061973A1 true AR061973A1 (es) | 2008-08-10 |
Family
ID=37895798
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP070103095A AR061973A1 (es) | 2006-07-14 | 2007-07-12 | Compuesto de 2-arilindol sustituido en la posicion 5, composicion farmaceutica que lo comprende, compuestos intermedios y procedimiento para la preparacion de los mismos |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US8017644B2 (es) |
| EP (1) | EP2049480B1 (es) |
| JP (1) | JP5302191B2 (es) |
| KR (2) | KR20140091569A (es) |
| CN (1) | CN101490000B (es) |
| AR (1) | AR061973A1 (es) |
| AU (1) | AU2007271865B2 (es) |
| BR (1) | BRPI0712889A8 (es) |
| CA (1) | CA2655750C (es) |
| DK (1) | DK2049480T3 (es) |
| EA (1) | EA015689B1 (es) |
| ES (1) | ES2441594T3 (es) |
| GE (1) | GEP20115166B (es) |
| IL (1) | IL196000A (es) |
| IT (1) | ITMI20061368A1 (es) |
| MX (1) | MX2009000492A (es) |
| PL (1) | PL2049480T3 (es) |
| PT (1) | PT2049480E (es) |
| SI (1) | SI2049480T1 (es) |
| UA (1) | UA96759C2 (es) |
| WO (1) | WO2008006663A1 (es) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2078711A1 (en) * | 2007-12-28 | 2009-07-15 | AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R.A.F. S.p.A. | (Aza)indole derivative substituted in position 5, pharmaceutical composition comprising it, intermediate compounds and preparation process therefor |
| CA2756870A1 (en) | 2009-03-31 | 2010-10-07 | Arqule, Inc. | Substituted indolo-pyridinone compounds |
| WO2011077313A1 (en) | 2009-12-22 | 2011-06-30 | Pfizer Inc. | Piperidinecarboxamides as mpges - 1 inhibitors |
| PT2746265E (pt) | 2011-08-18 | 2016-03-11 | Nippon Shinyaku Co Ltd | Derivado heterocíclico como inibidor de pronstaglandina-sintase microssomal (mpge) |
| WO2013038308A1 (en) * | 2011-09-15 | 2013-03-21 | Glenmark Pharmaceuticals S.A. | SUBSTITUTED BICYCLIC HETEROARYL COMPOUNDS AS mPGES-1 INHIBITORS |
| ES2838625T3 (es) * | 2014-04-14 | 2021-07-02 | Shanghai hengrui pharmaceutical co ltd | Derivados de amida y sales farmacéuticamente aceptables de los mismos, su método de preparación y aplicación médica de los mismos |
| JPWO2016021706A1 (ja) * | 2014-08-08 | 2017-05-25 | カズマパートナーズ株式会社 | 縮合複素環化合物 |
| CN112074505B (zh) | 2018-03-08 | 2024-04-05 | 因赛特公司 | 作为PI3K-γ抑制剂的氨基吡嗪二醇化合物 |
| US11046658B2 (en) | 2018-07-02 | 2021-06-29 | Incyte Corporation | Aminopyrazine derivatives as PI3K-γ inhibitors |
| JP7337260B2 (ja) * | 2019-08-26 | 2023-09-01 | クッジェ ファーマ カンパニー，リミテッド | インドールカルボキサミド誘導体及びそれを含む薬剤学的組成物 |
| WO2021231474A1 (en) * | 2020-05-12 | 2021-11-18 | Pmv Pharmaceuticals, Inc. | METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2003270426A1 (en) * | 2002-09-12 | 2004-04-30 | Avanir Pharmaceuticals | PHENYL-INDOLE COMPOUNDS FOR MODULATING IgE AND INHIBITING CELLULAR PROLIFERATION |
| JPWO2004069788A1 (ja) | 2003-02-07 | 2006-05-25 | 小野薬品工業株式会社 | カルボン酸化合物 |
| AP2006003534A0 (en) | 2003-09-03 | 2006-04-30 | Pfizer | Phenyl or pyridyl amide compounds as prostaglandin E2 antagonists. |
| ITTO20040125A1 (it) * | 2004-03-01 | 2004-06-01 | Rotta Research Lab | Nuove amidine eterocicliche inibitrici la produzione di ossido d'azoto (no) ad attivita' antinfiammatoria ed analgesica |
| GB0410121D0 (en) * | 2004-05-06 | 2004-06-09 | Glaxo Group Ltd | Compounds |
-
2006
- 2006-07-14 IT IT001368A patent/ITMI20061368A1/it unknown
-
2007
- 2007-06-14 US US12/306,426 patent/US8017644B2/en not_active Expired - Fee Related
- 2007-06-14 KR KR1020147014551A patent/KR20140091569A/ko not_active Ceased
- 2007-06-14 ES ES07786740.6T patent/ES2441594T3/es active Active
- 2007-06-14 DK DK07786740.6T patent/DK2049480T3/da active
- 2007-06-14 MX MX2009000492A patent/MX2009000492A/es active IP Right Grant
- 2007-06-14 EP EP07786740.6A patent/EP2049480B1/en active Active
- 2007-06-14 CA CA2655750A patent/CA2655750C/en not_active Expired - Fee Related
- 2007-06-14 UA UAA200814463A patent/UA96759C2/ru unknown
- 2007-06-14 GE GEAP200711112A patent/GEP20115166B/en unknown
- 2007-06-14 PT PT77867406T patent/PT2049480E/pt unknown
- 2007-06-14 PL PL07786740T patent/PL2049480T3/pl unknown
- 2007-06-14 SI SI200731381T patent/SI2049480T1/sl unknown
- 2007-06-14 AU AU2007271865A patent/AU2007271865B2/en not_active Ceased
- 2007-06-14 CN CN200780026647XA patent/CN101490000B/zh not_active Expired - Fee Related
- 2007-06-14 EA EA200970124A patent/EA015689B1/ru not_active IP Right Cessation
- 2007-06-14 JP JP2009518814A patent/JP5302191B2/ja not_active Expired - Fee Related
- 2007-06-14 KR KR1020097003017A patent/KR101440015B1/ko not_active Expired - Fee Related
- 2007-06-14 BR BRPI0712889A patent/BRPI0712889A8/pt not_active IP Right Cessation
- 2007-06-14 WO PCT/EP2007/055901 patent/WO2008006663A1/en not_active Ceased
- 2007-07-12 AR ARP070103095A patent/AR061973A1/es not_active Application Discontinuation
-
2008
- 2008-12-17 IL IL196000A patent/IL196000A/en active IP Right Grant
Also Published As
| Publication number | Publication date |
|---|---|
| ITMI20061368A1 (it) | 2008-01-15 |
| WO2008006663A1 (en) | 2008-01-17 |
| PT2049480E (pt) | 2013-12-16 |
| EP2049480A1 (en) | 2009-04-22 |
| AU2007271865B2 (en) | 2013-02-21 |
| SI2049480T1 (sl) | 2014-02-28 |
| IL196000A (en) | 2013-10-31 |
| UA96759C2 (en) | 2011-12-12 |
| US8017644B2 (en) | 2011-09-13 |
| BRPI0712889A8 (pt) | 2018-01-02 |
| EA015689B1 (ru) | 2011-10-31 |
| CN101490000B (zh) | 2012-10-03 |
| EA200970124A1 (ru) | 2009-06-30 |
| CA2655750C (en) | 2014-09-09 |
| KR101440015B1 (ko) | 2014-09-12 |
| DK2049480T3 (da) | 2014-01-20 |
| PL2049480T3 (pl) | 2014-03-31 |
| BRPI0712889A2 (pt) | 2012-10-09 |
| IL196000A0 (en) | 2009-09-01 |
| US20090186922A1 (en) | 2009-07-23 |
| MX2009000492A (es) | 2009-01-27 |
| JP5302191B2 (ja) | 2013-10-02 |
| HK1124068A1 (en) | 2009-08-07 |
| EP2049480B1 (en) | 2013-10-30 |
| AU2007271865A1 (en) | 2008-01-17 |
| KR20090054962A (ko) | 2009-06-01 |
| KR20140091569A (ko) | 2014-07-21 |
| JP2009543766A (ja) | 2009-12-10 |
| CA2655750A1 (en) | 2008-01-17 |
| GEP20115166B (en) | 2011-02-25 |
| ES2441594T3 (es) | 2014-02-05 |
| CN101490000A (zh) | 2009-07-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR061973A1 (es) | Compuesto de 2-arilindol sustituido en la posicion 5, composicion farmaceutica que lo comprende, compuestos intermedios y procedimiento para la preparacion de los mismos | |
| AR116993A2 (es) | Compuestos heterociclos bicíclicos y sus usos en terapia | |
| ES2525566T3 (es) | Nuevo derivado de hidroxamato, método para producirlo y composición farmacéutica que lo contiene | |
| CR20110013A (es) | Derivados de Heteroarilo como Inhibidores de DGAT1 | |
| ECSP099388A (es) | Derivados de azaadamatano y sus usos como ligandos de los receptores nicoticos de acetilcolina | |
| CO6321248A2 (es) | Derivados de triazol utiles para el tratamiento de enfermedades | |
| UY31940A (es) | Derivados sustituido del 4,5-(sustituido-piridin-3-il)-1-metil-1h-indol, sus sales farmacéuticamente aceptables, polimorfos, rotámeros, pro-fármacos, anantiómeros, hidratos, solvatos del mismo, composiciones conteniéndolos y aplicaciones | |
| EA201390163A1 (ru) | Гетеробициклические производные в качетстве ингибиторов hcv | |
| EA200700099A1 (ru) | Производные пиридина | |
| PE20121048A1 (es) | Derivados de imidazolidin-2-ona 1,3-disustituida como inhibidores de cyp17 | |
| AR086357A1 (es) | Derivados de indazol sustituidos activos como inhibidores de quinasas | |
| AR066155A1 (es) | Compuestos de pirazol, simil tiroideo, composicion farmaceutica, proceso y uso en terapia | |
| CL2009000127A1 (es) | Compuestos derivados de [indol, azaindol]-2-carboxamida sustituidos con un grupo silanilo; procedimiento de preparacion; compuestos intermediarios; composicion farmaceutica; y su uso en el tratamiento del dolor, inflamacion, trastornos metabolicos, entre otras enfermedades mediadas por la modulacion del receptor trpv1. | |
| AR094346A1 (es) | Derivados de azaindol como inhibidores de las proteína quinasas | |
| AR087915A1 (es) | N-(3-(2-amino-6,6-difluor-4,4a,5,6,7,7a-hexahidro-ciclopenta-[e][1,3]oxazin-4-il)-fenil)-amidas como inhibidores de la bace1 | |
| MX2022001158A (es) | Inhibidores dobles de atm y adn-pk para uso en terapias antitumorales. | |
| AR105522A1 (es) | Derivados de amida sustituida que tienen actividad multimodal contra el dolor | |
| AR069961A1 (es) | Derivados de (aza)indol sustituidos en la posicion 5 utiles en el tratamiento de la inflamacion y el dolor, composiciones farmaceuticas que los comprenden, proceso de preparacion de los mismos y compuestos intermediarios. | |
| AR051754A1 (es) | Metodos para preparar compuestos de indazol | |
| CR10206A (es) | Acidos4-fenil-tiazol-5-carboxilicos amidas de acidos 4-fenil-tiazol-5-carboxilicos como inhibidores de la plk1 | |
| MX389378B (es) | Derivados de amino-imidazopiridina novedosos como inhibidores de cinasa de janus y uso farmacéutico de estos. | |
| CO2022008690A2 (es) | Compuestos heterocíclicos como inhibidores de delta-5 desaturasa y métodos de uso | |
| EA200901391A1 (ru) | Пиримидинилпиперазины, применимые в качестве лигандов рецепторов d/d | |
| AR074353A1 (es) | Acidos naftalen-2-il-aceticos sustituidos, composiciones farmaceuticas que los contienen, y uso de los mismos en el tratamiento de enfermedades alergicas,tales como rinitis, asma y dermatititis atopica. | |
| CR11860A (es) | Derivados de dibenzotiazepina y sus usos - 424 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant, registration | ||
| FD | Application declared void or lapsed, e.g., due to non-payment of fee |